FrenkelM, SierpinaV, SapireK. Effects of complementary and integrative medicine on cancer survivorship. Curr Oncol Rep, 2015; 17:445.
2.
GreenleeH, DuPont‐ReyesMJ, BalneavesLG, et al.Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin, 2017; 67:194–232.
3.
CramerH, LaucheR, KloseP, et al.Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev, 2017; 1:CD010802.
4.
GodseyJ, GrundmannO. Review of various herbal supplements as complementary treatments for oral cancer. J Diet Suppl, 2016; 13:538–550.
5.
LeeA, ChanSK, FanLT. Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev, 2015:CD003281.
6.
MishraSI, SchererR, GeigleP, et al.Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev, 2009; DOI: 10.1002/14651858.CD008465.pub2.
7.
HermanPM, PoindexterBL, WittCM, EisenbergDM. Are complementary therapies and integrative care cost-effective? A systematic review of economic evaluations. BMJ Open, 2012; 2:e001046.
8.
HuebnerJ, ProttFJ, MueckeR, et al.Economic evaluation of complementary and alternative medicine in oncology: Is there a difference compared to conventional medicine?. Med Princ Pract, 2017; 26:41–49.
9.
MariottoAB, Robin YabroffK, ShaoY, et al.Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst, 2011; 103:117–128.
10.
SingleterryJ. Cancer Action Network. The Costs of Cancer: Addressing Patient Costs. Washington, DC: American Cancer Society, 2017.
11.
ZafarSY, NewcomerLN, McCarthyJ, et al.How should we intervene on the financial toxicity of cancer care? One shot, four perspectives. Am Soc Clin Oncol Educ Book, 2017; 37:35–39.
12.
GoldsteinDA. Financial toxicity in cancer care—Edging toward solutions. Cancer, 2017; 123:1301–1302.
13.
Casilla-LennonMM, ChoiSK, DealAM, et al.Financial toxicity in patients with bladder cancer: Reasons for delay in care and effect on quality of life. J Urol, 2018; 199:1166–1173.
14.
Kaiser Family Foundation. Employer health benefits survey, 2016. 2016. Online document at: http://kff.org/health-costs/report/2016-employer-health-benefitssurvey/, accessed March26, 2018.
15.
ChinoF, PeppercornJM, RushingC, et al.Out-of-pocket costs, financial distress, and underinsurance in cancer care. JAMA Oncol, 2017; 3:1582–1584.
16.
RowlandC, HanrattyB, PillingM, et al.The contributions of family care-givers at end of life: A national post-bereavement census survey of cancer carers' hours of care and expenditures. Palliat Med, 2017; 31:346–355.
17.
WongY-N, EglestonBL, SachdevaK, et al.Cancer patients' trade-offs among efficacy, toxicity and out-of-pocket cost in the curative and non-curative setting. Med Care, 2013; 51:838–845.
18.
ZafarSY, PeppercornJM, SchragD, et al.The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist, 2013; 18:381–390.
19.
RamseyS, BloughD, KirchhoffA, et al.Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff, 2013; 32:1143–1152.
20.
StubT, QuandtSA, ArcuryTA, et al.Perception of risk and communication among conventional and complementary health care providers involving cancer patients' use of complementary therapies: A literature review. BMC Complement Altern Med, 2016; 16:353.
21.
EschitiVS. Lesson from comparison of CAM use by women with female-specific cancers to others: It's time to focus on interaction risks with CAM therapies. Integr Cancer Ther, 2007; 6:313–344.
22.
HorneberM, BueschelG, DennertG, et al.How many cancer patients use complementary and alternative medicine: A systematic review and metaanalysis. Integr Cancer Ther, 2012; 11:187–203.
23.
MolassiotisA, Fernadez-OrtegaP, PudD, et al.Use of complementary and alternative medicine in cancer patients: A European survey. Ann Oncol, 2005; 16:655–663.
24.
StandishLJ, DowdF, SweetE, et al.Breast cancer integrative oncology care and its costs. Integr Cancer Ther, 2017; 16:85–95.
25.
HermanPM. Evaluating the economics of complementary and integrative medicine. Glob Adv Health Med, 2013; 2:56–63.
26.
DrummondMF, SculpherMJ, TorranceGW, et al.Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Oxford: Oxford University Press, 2005.
27.
JacobsenPB, MeadeCD, SteinKD, et al.Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol, 2002; 20:2851–2862.
28.
ForchukC, BaruthP, PrendergastM, et al.Postoperative arm massage: A support for women with lymph node dissection. Cancer Nurs, 2004; 27:25–33.
BragaM, GianottiL, VignaliA, et al.Hospital resources consumed for surgical morbidity: Effects of preoperative arginine and ω-3 fatty acid supplementation on costs. Nutrition, 2005; 21:1078–1086.
31.
LangEV, BerbaumKS, FaintuchS, et al.Adjunctive self-hypnotic relaxation for outpatient medical procedures: A prospective randomized trial with women undergoing large core breast biopsy. Pain, 2006; 126:155–164.
32.
MontgomeryGH, BovbjergDH, SchnurJB, et al.A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst, 2007; 99:1304–1312.
33.
ChengJ-H, LiuW-S, LiZ-M, WangZ-G. A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer. Chin J Integr Med, 2007; 13:269–274.
34.
MolassiotisA, RussellW, HughesJ, et al.The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial. Health Technol Assess, 2013; 17:1–114.
35.
LiuY-Q, SunS, DongH-I, et al.Wrist-ankle acupuncture and ginger moxibustion for preventing gastrointestinal reactions to chemotherapy: A randomized controlled trial. Chin J Integr Med, 2015; 21:697–702.
36.
LaffertyWE, TyreePT, BellasAS, et al.Insurance coverage and subsequent utilization of complementary and alternative medical (CAM) providers. Am J Manag Care, 2006; 12:397.
37.
Landmark Healthcare. The Landmark Report II on HMOs and Alternative Care. Sacramento, CA: Landmark Healthcare Inc., 1999.
